Your browser doesn't support javascript.
loading
Dosimetric comparison of proton therapy and CyberKnife in stereotactic body radiation therapy for liver cancers.
Shyllon, Samuel; Penfold, Scott; Dalfsen, Ray; Kirkness, Elsebe; Hug, Ben; Rowshanfarzad, Pejman; Devlin, Peter; Tang, Colin; Le, Hien; Gorayski, Peter; Grogan, Garry; Kearvell, Rachel; Ebert, Martin A.
Afiliação
  • Shyllon S; School of Physics, Mathematics and Computing, The University of Western Australia, Perth, WA, Australia.
  • Penfold S; Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Dalfsen R; Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia.
  • Kirkness E; Department of Physics, University of Adelaide, Adelaide, SA, Australia.
  • Hug B; Australian Bragg Centre for Proton Therapy and Research, Adelaide, SA, Australia.
  • Rowshanfarzad P; PT Product Engineering, Elekta, Adelaide, SA, Australia.
  • Devlin P; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
  • Tang C; 5D Clinics, Claremont, WA, Australia.
  • Le H; School of Physics, Mathematics and Computing, The University of Western Australia, Perth, WA, Australia. pejman.rowshanfarzad@uwa.edu.au.
  • Gorayski P; Centre for Advanced Technologies in Cancer Research (CATCR), Perth, WA, Australia. pejman.rowshanfarzad@uwa.edu.au.
  • Grogan G; Icon Cancer Centre, Midland, WA, Australia.
  • Kearvell R; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
  • Ebert MA; 5D Clinics, Claremont, WA, Australia.
Phys Eng Sci Med ; 2024 May 29.
Article em En | MEDLINE | ID: mdl-38809365
ABSTRACT
Stereotactic body radiation therapy (SBRT) has been increasingly used for the ablation of liver tumours. CyberKnife and proton beam therapy (PBT) are two advanced treatment technologies suitable to deliver SBRT with high dose conformity and steep dose gradients. However, there is very limited data comparing the dosimetric characteristics of CyberKnife to PBT for liver SBRT. PBT and CyberKnife plans were retrospectively generated using 4DCT datasets of ten patients who were previously treated for hepatocellular carcinoma (HCC, N = 5) and liver metastasis (N = 5). Dose volume histogram data was assessed and compared against selected criteria; given a dose prescription of 54 Gy in 3 fractions for liver metastases and 45 Gy in 3 fractions for HCC, with previously published consensus-based normal tissue dose constraints. Comparison of evaluation parameters showed a statistically significant difference for target volume coverage and liver, lungs and spinal cord (p < 0.05) dose, while chest wall and skin did not indicate a significant difference between the two modalities. A number of optimal normal tissue constraints was violated by both the CyberKnife and proton plans for the same patients due to proximity of tumour to chest wall. PBT resulted in greater organ sparing, the extent of which was mainly dependent on tumour location. Tumours located on the liver periphery experienced the largest increase in organ sparing. Organ sparing for CyberKnife was comparable with PBT for small target volumes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article